Eintrag weiter verarbeiten
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Pos...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 30(2012), 35, Seite 4323-4329 |
|---|---|
| Personen und Körperschaften: | , |
| Titel: | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib/ Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
2012
|
| Gesamtaufnahme: |
: Journal of clinical oncology, 30(2012), 35, Seite 4323-4329
, volume:30 |
| Erscheint auch als: | Branford, Susan, Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib, 2012 |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 04576caa a2200553 4500 | ||
|---|---|---|---|
| 001 | 0-1576449033 | ||
| 003 | DE-627 | ||
| 005 | 20220814164959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180618s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.40.5217 |2 doi | |
| 035 | |a (DE-627)1576449033 | ||
| 035 | |a (DE-576)506449033 | ||
| 035 | |a (DE-599)BSZ506449033 | ||
| 035 | |a (OCoLC)1341011868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Branford, Susan |e VerfasserIn |0 (DE-588)1169778755 |0 (DE-627)1035883791 |0 (DE-576)512242151 |4 aut | |
| 245 | 1 | 0 | |a Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |c Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
| 264 | 1 | |c 2012 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online ahead of print at www.jco.org on October 29, 2012 | ||
| 500 | |a Gesehen am 18.06.2018 | ||
| 520 | |a Purpose The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients and Methods Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline BCR-ABL1 transcript assessments were included (N = 237). Results BCR-ABL1 transcript levels (International Scale [IS]) at 3 months correlated with complete cytogenetic response (CCyR) by 24 months. Patients with BCR-ABL1 (IS) of > 1% to ≤ 10% at 3 months with nilotinib had higher cumulative incidence of CCyR by 24 months than patients with BCR-ABL1 (IS) of > 10% (53% v 16%). BCR-ABL1 (IS) at 3 months predicted major molecular response (MMR) by 24 months. Cumulative incidence of MMR by 24 months for patients with BCR-ABL1 (IS) of > 0.1% to ≤ 1%, > 1% to ≤ 10%, and > 10% was 65%, 27%, and 9%, respectively. These differences were observed for patients with or without baseline BCR-ABL1 mutations and for those with imatinib resistance or intolerance. Estimated event-free survival (EFS) rates at 24 months decreased with higher transcript levels at 3 months; patients with BCR-ABL1 (IS) of ≤ 1% had an estimated 24-month EFS rate of 82%, compared with 70% for patients with BCR-ABL1 (IS) of > 1% to ≤ 10% and 48% for patients with BCR-ABL1 (IS) of > 10%. Conclusion Patients with BCR-ABL1 (IS) of > 10% at 3 months had a lower cumulative incidence of CCyR and MMR and lower rates of EFS versus patients with BCR-ABL1 (IS) of ≤ 10%. Prospective studies may determine whether close monitoring or alternative therapies are warranted for patients with minimal initial molecular response. | ||
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 35, Seite 4323-4329 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:35 |g pages:4323-4329 |g extent:7 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Branford, Susan |t Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib |d 2012 |w (DE-627)1447642732 |w (DE-576)377642738 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.40.5217 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2011.40.5217 |x Verlag |z kostenfrei |3 Volltext |
| 936 | u | w | |d 30 |j 2012 |e 35 |h 4323-4329 |g 7 |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.40.5217 |9 LFER |
| 852 | |a LFER |z 2018-10-10T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Müller, Martin C. | ||
| 900 | |a Muller, M. | ||
| 900 | |a Müller, M. C. | ||
| 900 | |a Mueller, Martin C. | ||
| 900 | |a Müller, Martin | ||
| 951 | |b XE-AU | ||
| 980 | |a 1576449033 |b 0 |k 1576449033 |o 506449033 |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Initial+Molecular+Response+at+3+Months+May+Predict+Both+Response+and+Event-Free+Survival+at+24+Months+in+Imatinib-Resistant+or+-Intolerant+Patients+With+Philadelphia+Chromosome-Positive+Chronic+Myeloid+Leukemia+in+Chronic+Phase+Treated+With+Nilotinib&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Branford%2C+Susan&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1527-7755 |
|---|
| _version_ | 1757949667899867136 |
|---|---|
| access_facet | Electronic Resources |
| author | Branford, Susan, Müller, Martin Christian |
| author_facet | Branford, Susan, Müller, Martin Christian |
| author_role | aut, aut |
| author_sort | Branford, Susan |
| author_variant | s b sb, m c m mc mcm |
| callnumber-sort | |
| collection | lfer |
| container_reference | 30(2012), 35, Seite 4323-4329 |
| container_title | Journal of clinical oncology |
| contents | Purpose The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients and Methods Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline BCR-ABL1 transcript assessments were included (N = 237). Results BCR-ABL1 transcript levels (International Scale [IS]) at 3 months correlated with complete cytogenetic response (CCyR) by 24 months. Patients with BCR-ABL1 (IS) of > 1% to ≤ 10% at 3 months with nilotinib had higher cumulative incidence of CCyR by 24 months than patients with BCR-ABL1 (IS) of > 10% (53% v 16%). BCR-ABL1 (IS) at 3 months predicted major molecular response (MMR) by 24 months. Cumulative incidence of MMR by 24 months for patients with BCR-ABL1 (IS) of > 0.1% to ≤ 1%, > 1% to ≤ 10%, and > 10% was 65%, 27%, and 9%, respectively. These differences were observed for patients with or without baseline BCR-ABL1 mutations and for those with imatinib resistance or intolerance. Estimated event-free survival (EFS) rates at 24 months decreased with higher transcript levels at 3 months; patients with BCR-ABL1 (IS) of ≤ 1% had an estimated 24-month EFS rate of 82%, compared with 70% for patients with BCR-ABL1 (IS) of > 1% to ≤ 10% and 48% for patients with BCR-ABL1 (IS) of > 10%. Conclusion Patients with BCR-ABL1 (IS) of > 10% at 3 months had a lower cumulative incidence of CCyR and MMR and lower rates of EFS versus patients with BCR-ABL1 (IS) of ≤ 10%. Prospective studies may determine whether close monitoring or alternative therapies are warranted for patients with minimal initial molecular response. |
| ctrlnum | (DE-627)1576449033, (DE-576)506449033, (DE-599)BSZ506449033, (OCoLC)1341011868 |
| doi_str_mv | 10.1200/JCO.2011.40.5217 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0021321331 |
| footnote | Published online ahead of print at www.jco.org on October 29, 2012, Gesehen am 18.06.2018 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | Australia |
| hierarchy_parent_id | 0-313116962 |
| hierarchy_parent_title | Journal of clinical oncology |
| hierarchy_sequence | 30(2012), 35, Seite 4323-4329 |
| hierarchy_top_id | 0-313116962 |
| hierarchy_top_title | Journal of clinical oncology |
| id | 0-1576449033 |
| illustrated | Not Illustrated |
| imprint | 2012 |
| imprint_str_mv | 2012 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-1576449033 |
| is_hierarchy_title | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |
| isil_str_mv | LFER |
| issn | 1527-7755 |
| kxp_id_str | 1576449033 |
| language | English |
| last_indexed | 2023-02-16T01:37:27.229Z |
| marc024a_ct_mv | 10.1200/JCO.2011.40.5217 |
| match_str | branford2012initialmolecularresponseat3monthsmaypredictbothresponseandeventfreesurvivalat24monthsinimatinibresistantorintolerantpatientswithphiladelphiachromosomepositivechronicmyeloidleukemiainchronicphasetreatedwithnilotinib |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 090887018 |
| multipart_part | (090887018)30(2012), 35, Seite 4323-4329 |
| names_id_str_mv | (DE-588)1169778755, (DE-627)1035883791, (DE-576)512242151, (DE-588)121360296, (DE-627)705409236, (DE-576)181482819 |
| oclc_num | 1341011868 |
| physical | 7 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 506449033 |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Branford, Susan VerfasserIn (DE-588)1169778755 (DE-627)1035883791 (DE-576)512242151 aut, Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller, 2012, 7, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Published online ahead of print at www.jco.org on October 29, 2012, Gesehen am 18.06.2018, Purpose The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients and Methods Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline BCR-ABL1 transcript assessments were included (N = 237). Results BCR-ABL1 transcript levels (International Scale [IS]) at 3 months correlated with complete cytogenetic response (CCyR) by 24 months. Patients with BCR-ABL1 (IS) of > 1% to ≤ 10% at 3 months with nilotinib had higher cumulative incidence of CCyR by 24 months than patients with BCR-ABL1 (IS) of > 10% (53% v 16%). BCR-ABL1 (IS) at 3 months predicted major molecular response (MMR) by 24 months. Cumulative incidence of MMR by 24 months for patients with BCR-ABL1 (IS) of > 0.1% to ≤ 1%, > 1% to ≤ 10%, and > 10% was 65%, 27%, and 9%, respectively. These differences were observed for patients with or without baseline BCR-ABL1 mutations and for those with imatinib resistance or intolerance. Estimated event-free survival (EFS) rates at 24 months decreased with higher transcript levels at 3 months; patients with BCR-ABL1 (IS) of ≤ 1% had an estimated 24-month EFS rate of 82%, compared with 70% for patients with BCR-ABL1 (IS) of > 1% to ≤ 10% and 48% for patients with BCR-ABL1 (IS) of > 10%. Conclusion Patients with BCR-ABL1 (IS) of > 10% at 3 months had a lower cumulative incidence of CCyR and MMR and lower rates of EFS versus patients with BCR-ABL1 (IS) of ≤ 10%. Prospective studies may determine whether close monitoring or alternative therapies are warranted for patients with minimal initial molecular response., Müller, Martin Christian 1972- VerfasserIn (DE-588)121360296 (DE-627)705409236 (DE-576)181482819 aut, Enthalten in Journal of clinical oncology Alexandria, Va. : American Society of Clinical Oncology, 1983 30(2012), 35, Seite 4323-4329 Online-Ressource (DE-627)313116962 (DE-600)2005181-5 (DE-576)090887018 1527-7755 nnns, volume:30 year:2012 number:35 pages:4323-4329 extent:7, Erscheint auch als Druck-Ausgabe Branford, Susan Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib 2012 (DE-627)1447642732 (DE-576)377642738, http://dx.doi.org/10.1200/JCO.2011.40.5217 Verlag Resolving-System kostenfrei Volltext, http://ascopubs.org/doi/10.1200/JCO.2011.40.5217 Verlag kostenfrei Volltext, http://dx.doi.org/10.1200/JCO.2011.40.5217 LFER, LFER 2018-10-10T00:00:00Z |
| spellingShingle | Branford, Susan, Müller, Martin Christian, Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib, Purpose The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients and Methods Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline BCR-ABL1 transcript assessments were included (N = 237). Results BCR-ABL1 transcript levels (International Scale [IS]) at 3 months correlated with complete cytogenetic response (CCyR) by 24 months. Patients with BCR-ABL1 (IS) of > 1% to ≤ 10% at 3 months with nilotinib had higher cumulative incidence of CCyR by 24 months than patients with BCR-ABL1 (IS) of > 10% (53% v 16%). BCR-ABL1 (IS) at 3 months predicted major molecular response (MMR) by 24 months. Cumulative incidence of MMR by 24 months for patients with BCR-ABL1 (IS) of > 0.1% to ≤ 1%, > 1% to ≤ 10%, and > 10% was 65%, 27%, and 9%, respectively. These differences were observed for patients with or without baseline BCR-ABL1 mutations and for those with imatinib resistance or intolerance. Estimated event-free survival (EFS) rates at 24 months decreased with higher transcript levels at 3 months; patients with BCR-ABL1 (IS) of ≤ 1% had an estimated 24-month EFS rate of 82%, compared with 70% for patients with BCR-ABL1 (IS) of > 1% to ≤ 10% and 48% for patients with BCR-ABL1 (IS) of > 10%. Conclusion Patients with BCR-ABL1 (IS) of > 10% at 3 months had a lower cumulative incidence of CCyR and MMR and lower rates of EFS versus patients with BCR-ABL1 (IS) of ≤ 10%. Prospective studies may determine whether close monitoring or alternative therapies are warranted for patients with minimal initial molecular response. |
| swb_id_str | 506449033 |
| title | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |
| title_auth | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |
| title_full | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
| title_fullStr | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
| title_full_unstemmed | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
| title_in_hierarchy | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib / Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller, |
| title_short | Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |
| title_sort | initial molecular response at 3 months may predict both response and event free survival at 24 months in imatinib resistant or intolerant patients with philadelphia chromosome positive chronic myeloid leukemia in chronic phase treated with nilotinib |
| url | http://dx.doi.org/10.1200/JCO.2011.40.5217, http://ascopubs.org/doi/10.1200/JCO.2011.40.5217 |